UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 30, 2014

A	LEXION PHARMACEUTICALS, INC.	_
(Exact	name of registrant as specified in its char	ter)
Delaware	000-27756	13-3648318
State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
352 1	Knotter Drive, Cheshire, Connecticut 064	
(Addre	ess of Principal Executive Offices) (Zip Co	
Registrant's tel	ephone number, including area code: (2	03) 272-2596
the appropriate box below if the Form 8-K lowing provisions (<i>see</i> General Instruction		the filing obligation of the registrant under any
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		

Item 8.01 Other Events.

On July 30, 2014, Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, Inc., reported sales of Alexion common stock made under a pre-arranged stock trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Dr. Bell's currently existing pre-arranged stock trading plans adopted in accordance with Rule 10b5-1 for, among other things, estate and family financial planning, provide for the sale of up to an additional 227,182 shares of Alexion common stock.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 30, 2014 ALEXION PHARMACEUTICALS, INC.

By: <u>/s/ Michael V. Greco</u> Name: Michael V. Greco

Title: Vice President of Law and Corporate Secretary